Clinical trial tracker

Clinical trial tracker

Looking for Lilly’s LY4086940? Its two registered trials, NCT06945419 and NCT07890376, are listed below. For what they test and what has not been disclosed, see the LY4086940 profile or our LY4086940 write-up.

Reset

134 registered trials, newest registry update first.

TrialCompoundPhaseStatusSponsorEnrolledPrimary completionRegistry updated
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
NCT07881432
EloralintidePhase 3Not yet recruitingEli Lilly and Company2,115Oct 2029Nov 17, 2026
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
NCT07900633
None linkedPhase 3Not yet recruitingEli Lilly and Company3,000Nov 2029Nov 17, 2026
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
NCT06745284
SurvodutidePhase 1Active not recruitingBoehringer Ingelheim64Nov 1, 2026Nov 16, 2026
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
NCT07220759
CagrilintidePhase 3Active not recruitingNovo Nordisk A/S330May 12, 2027Nov 16, 2026
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
NCT07868835
VK2735Phase 3RecruitingViking Therapeutics, Inc.560Jul 2028Nov 16, 2026
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
NCT07868939
VK2735Phase 3RecruitingViking Therapeutics, Inc.560Oct 2028Nov 16, 2026
A Study Assessing Eloralintide (LY3841136) in Healthy Participants
NCT07935304
EloralintidePhase 1Not yet recruitingEli Lilly and Company90Apr 2027Nov 13, 2026
LIVERAGE™ – Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457
SurvodutidePhase 3RecruitingBoehringer Ingelheim1,590Jun 5, 2029Nov 12, 2026
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
NCT07437560
Melanotan 2Phase 2RecruitingHudson Biotech60Feb 14, 2027Nov 12, 2026
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
NCT06299098
TrevogrumabPhase 2CompletedRegeneron Pharmaceuticals1,005Jun 16, 2026Nov 12, 2026
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
NCT05936151
RetatrutidePhase 2CompletedEli Lilly and Company146Oct 1, 2025Nov 9, 2026
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045
Enicepatide (CT-388)Phase 3RecruitingHoffmann-La Roche2,000Jul 24, 2028Nov 9, 2026
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058
Enicepatide (CT-388)Phase 3RecruitingHoffmann-La Roche1,600Aug 7, 2028Nov 9, 2026
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants
NCT07626515
Enicepatide (CT-388)Phase 1Active not recruitingHoffmann-La Roche36Apr 8, 2027Nov 5, 2026
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
NCT07670416
Enicepatide (CT-388)Phase 3RecruitingHoffmann-La Roche300Feb 24, 2028Nov 5, 2026
UBT251 Injection Phase II Study (Overweight or Obesity)
NCT07177469
UBT251Phase 2CompletedThe United Bio-Technology (Hengqin) Co., Ltd.205Oct 22, 2025Nov 5, 2026
UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study
NCT07163624
UBT251Phase 2CompletedThe United Bio-Technology (Hengqin) Co., Ltd.211Nov 21, 2025Nov 5, 2026
UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)
NCT07648225
UBT251Phase 3Active not recruitingThe United Bio-Technology (Hengqin) Co., Ltd.600Sep 29, 2027Nov 5, 2026
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475
NisotirostidePhase 2RecruitingEli Lilly and Company200May 2027Nov 4, 2026
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953
BrenipatidePhase 3RecruitingEli Lilly and Company1,100Apr 2028Nov 4, 2026
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756
BrenipatidePhase 3RecruitingEli Lilly and Company1,000Feb 2028Nov 4, 2026
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
NCT07881458
EloralintidePhase 3RecruitingEli Lilly and Company1,000Oct 2029Nov 4, 2026
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
NCT07890376
LY4086940Phase 2Not yet recruitingEli Lilly and Company460Jan 2028Nov 3, 2026
UBT251 Injection Phase II Clinical Study (CKD)
NCT07134335
UBT251Phase 2RecruitingThe United Bio-Technology (Hengqin) Co., Ltd.180Jul 11, 2030Nov 3, 2026
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
NCT07145151
UBT251Phase 2RecruitingThe United Bio-Technology (Hengqin) Co., Ltd.156Jun 4, 2027Nov 3, 2026
UBT251 Injection Phase Ⅲ Study (OSA-NPAP)
NCT07767942
UBT251Phase 3Not yet recruitingThe United Bio-Technology (Hengqin) Co., Ltd.150Sep 2028Nov 3, 2026
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
NCT06628362
Enicepatide (CT-388)Phase 2CompletedCarmot Therapeutics, Inc.447May 29, 2026Oct 28, 2026
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444
SurvodutidePhase 3RecruitingBoehringer Ingelheim1,800Dec 27, 2031Oct 28, 2026
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
NCT07607587
CagrilintidePhase 1RecruitingNovo Nordisk A/S114Nov 19, 2027Oct 19, 2026
A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight
NCT07808060
EloralintidePhase 1RecruitingEli Lilly and Company34Jun 2027Oct 8, 2026
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966
BrenipatidePhase 3RecruitingEli Lilly and Company1,100Apr 2028Oct 7, 2026
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
NCT07668388
UBT251Phase 2RecruitingNovo Nordisk A/S300Oct 4, 2027Oct 7, 2026
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
NCT06525935
Enicepatide (CT-388)Phase 2CompletedCarmot Therapeutics, Inc.469Dec 8, 2025Oct 5, 2026
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796
CagrilintidePhase 3Active not recruitingNovo Nordisk A/S3,400Oct 30, 2024Sep 30, 2026
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
NCT06606106
BrenipatidePhase 1Active not recruitingEli Lilly and Company302Nov 2026Sep 30, 2026
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT06603571
EloralintidePhase 2CompletedEli Lilly and Company367Jul 1, 2026Sep 29, 2026
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722
RetatrutidePhase 3Active not recruitingEli Lilly and Company1,250Aug 27, 2026Sep 28, 2026
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
NCT07720271
AmycretinPhase 3RecruitingNovo Nordisk A/S950Jun 27, 2028Sep 28, 2026
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
NCT06131372
CagrilintidePhase 2CompletedNovo Nordisk A/S626Sep 24, 2025Sep 24, 2026
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone(UNIGUIDE-1)
NCT07659574
UBT251Phase 3RecruitingThe United Bio-Technology (Hengqin) Co., Ltd.360Sep 24, 2027Sep 15, 2026
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
NCT07653477
UBT251Phase 3RecruitingThe United Bio-Technology (Hengqin) Co., Ltd.956Feb 29, 2028Sep 14, 2026
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT06649045
OrforglipronPhase 3CompletedEli Lilly and Company712Jul 21, 2026Sep 14, 2026
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
NCT07010432
CagrilintidePhase 1RecruitingNovo Nordisk A/S144May 3, 2028Sep 10, 2026
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
NCT07184086
CagrilintidePhase 1Active not recruitingNovo Nordisk A/S80Oct 12, 2027Sep 10, 2026
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
NCT05202353
SurvodutidePhase 1Active not recruitingBoehringer Ingelheim29Jan 6, 2027Sep 9, 2026
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
NCT06323161
CagrilintidePhase 3CompletedNovo Nordisk A/S274Sep 9, 2025Sep 9, 2026
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
NCT06926842
PetrelintidePhase 2CompletedZealand Pharma221Aug 13, 2026Sep 9, 2026
UBT251 Injection Phase Ⅲ Study (OSA-PAP)
NCT07806851
UBT251Phase 3Not yet recruitingThe United Bio-Technology (Hengqin) Co., Ltd.150Mar 2029Sep 8, 2026
Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism
NCT04648969
Kisspeptin-10Phase 2CompletedStephanie B. Seminara, MD18Aug 31, 2025Aug 26, 2026
A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant
NCT07710729
UBT251Phase 1RecruitingNovo Nordisk A/S40Apr 27, 2027Aug 25, 2026

Page 1 of 3 Older →

Data: ClinicalTrials.gov, U.S. National Library of Medicine. Registered trials only. This table does not report results or recommend anything.